New research has uncovered immune changes in cancer patients that could help identify which patients are most at risk of dangerous heart complications from cancer drugs, known as immune checkpoint ...

Predictive implications of immune-related adverse events after exposure to VEGF inhibitors on outcomes in patients with advanced NSCLC treated with prior immune check point inhibitor. This is an ASCO ...

Real-world time on treatment (rwTOT) with first-line (1L) enfortumab vedotin and pembrolizumab (EV+P) after U.S. Food and Drug Administration approval for advanced urothelial cancer (aUC). This is an ...

ICIs combined with chemotherapy showed higher efficacy than bevacizumab in treating advanced driver gene–negative NS-NSCLC. The study reported improved PFS and OS for patients receiving ICIs compared ...

ICI-based combinations, especially with TKI, improved survival in heavily pretreated MSS mCRC patients, showing a median OS of 11.8 months and PFS of 4.6 months. Liver metastasis negatively impacted ...

Please provide your email address to receive an email when new articles are posted on . People with cancer who received statins during immune checkpoint inhibitor therapy had improved prognosis.

When immune checkpoint inhibitors are used in cancer treatment, in some cases it can lead to severe inflammation and damage to heart tissue. Histology images of mouse heart tissue illustrate the ...

WASHINGTON — Immune checkpoint inhibitor (ICI) therapy does not increase mortality in people with preexisting autoimmune diseases, new research has found. Results from a large database analysis of ...

This Research Topic is one volume within the series "The Future of Checkpoint Immunotherapy: New Roads Ahead". Please see the ...

Please provide your email address to receive an email when new articles are posted on . Patients who received PD-1 or PD-L1 agents exhibited increased risk for psoriasis. Medical professionals should ...

Checkpoint inhibitors are a groundbreaking class of cancer treatment, but they come with two frustrating challenges. In some cases, tumors show no initial response, rendering the therapy ineffective ...